PCSA — Processa Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00Annual balance sheet for Processa Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 16.5 | 6.5 | 4.71 | 1.19 | 5.54 |
| Net Total Receivables | 0.07 | — | — | — | — |
| Prepaid Expenses | |||||
| Total Current Assets | 18.3 | 8.39 | 5.63 | 1.87 | 5.67 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.074 | 0.228 | 0.149 | 0.076 | 0.004 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 26.5 | 8.62 | 5.79 | 3.23 | 7.81 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.971 | 0.999 | 0.731 | 1.53 | 2.24 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 0.978 | 1.15 | 0.797 | 1.53 | 2.24 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Total Equity | 25.5 | 7.47 | 4.99 | 1.7 | 5.58 |
| Total Liabilities & Shareholders' Equity | 26.5 | 8.62 | 5.79 | 3.23 | 7.81 |
| Total Common Shares Outstanding |